Israel-India partnership advances new osteoarthritis treatment

ANI

Updated At : 06:01 PM Apr 24, 2025 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

Tel Aviv [Israel], April 24 (ANI/ TPS): India's Sun Pharma and Israel's Moebius Medical published new data on MM-II, a non-opioid treatment for knee osteoarthritis. The studies, featured in the peer-reviewed Osteoarthritis and Cartilage journal, show that a single injection of MM-II can provide long-lasting pain relief and protect cartilage.

The drug, developed in Israel and supported by Sun Pharma, recently received Fast Track Designation from the US FDA. New findings will be presented at the OARSI 2025 World Congress. (ANI/ TPS)

(The story has come from a syndicated feed and has not been edited by the Tribune Staff.)

Tags :

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles